Conditions: Oral Mucositis
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 111
Healthy volunteers: no

Brief summary:
To evaluate the safety and efficacy of SGX942 in patients receiving chemoradiation treatment for the treatment of head and neck cancer.

Detailed description:

Arms:
arm 1: Control arm 2: Investigational Drug i) 1.5 mg/kg ii) 3.0 mg/kg iii) 6.0 mg/kg

Interventions: intervention 1: SGX942 intervention 2: Placebo
Intervention descriptions: intervention 1: None intervention 2: None

Protocol document: